Jean-Louis Pujol - Concepedia

Author

Jean-Louis Pujol

Hôpital Arnaud de Villeneuve ORCID

Also Known As

J L Pujol, J López Pujol, J PUJOL, J Pujol, J-L Pujol, J. -L. Pujol, J. L. Pujol, J. Pujol, J.-L. Pujol, J.L. Pujol

243

Publications

Citations

H-Index

Concepts

All Affiliations

Hôpital Arnaud de Villeneuve Centre Hospitalier Universitaire de Montpellier Université de Montpellier Inserm Institut de Recherche en Cancérologie de Montpellier

About

Jean-Louis Pujol is an author at Hôpital Arnaud de Villeneuve specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	54	4.4K
2	Health Sciences	12	14	672
3	Public Health	2	2	62
4	Allergy	2	2	122
5	Education	1	1	11

Jean-Louis Pujol

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio, The Lancet Advanced Lung DiseaseMedicinePathologyCancer GenomicsMolecular Diagnostics	2016	969
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol, Journal of Clinical Oncology	2007	380
Perioperative Nivolumab in Resectable Lung Cancer Tina Cascone, Mark M. Awad, Jonathan Spicer, New England Journal of Medicine	2024	356
Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer Jean-Louis Pujol, Jean‐Christophe Grenier, J.-P. Daurès, Lung Cancer Cytokeratin Subunit 19Advanced Lung DiseaseMedicineImmunologySerum Fragment	1993	320
Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer Joachim von Pawel, U. Gatzemeier, Jean-Louis Pujol, Journal of Clinical Oncology	2001	233
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Journal of Thoracic Oncology MedicinePharmacologyPathologyImmune Checkpoint InhibitorBronchial Neoplasm	2019	181
Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study Jean-Louis Pujol, Jean Pierre Daurès, Aart Brutel de la Rivière, JNCI Journal of the National Cancer Institute	2001	173
Carcinoid tumors of the lung: Do atypical features require aggressive management? Charles-Henri Marty-Ané, Valérie Costes, Jean-Louis Pujol, The Annals of Thoracic Surgery Malignant DiseaseMedicineAtypical FeaturesPathologyAggressive Management	1995	166
Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin Jean-Louis Pujol, Jean-Luc Breton, R. Gervais, Annals of Oncology Gemcitabine–docetaxel Versus Cisplatin–vinorelbineMedicineAnti-cancer AgentPhase Iii StudyCancer Treatment	2005	129

Page 1